{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:22:50Z","timestamp":1791595370938,"version":"4.3.4"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515010708"],"award-info":[{"award-number":["2021A1515010708"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2016A020215149"],"award-info":[{"award-number":["2016A020215149"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.intimp.2022.108821","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T07:08:17Z","timestamp":1651734497000},"page":"108821","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"109","author":[{"given":"Yunguang","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiting","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanghui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-580X","authenticated-orcid":false,"given":"Zhigang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2022.108821_b0005","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.critrevonc.2015.08.020","article-title":"Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays","volume":"97","author":"Bennour","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.intimp.2022.108821_b0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.intimp.2022.108821_b0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.intimp.2022.108821_b0020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fonc.2019.00603","article-title":"Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety","volume":"9","author":"Garc\u00eda-Guti\u00e9rrez","year":"2019","journal-title":"Front Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108821_b0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11912-018-0665-2","article-title":"The Cure of Chronic Myeloid Leukemia: Are We There Yet?","volume":"20","author":"Saikia","year":"2018","journal-title":"Current oncol. reports"},{"key":"10.1016\/j.intimp.2022.108821_b0030","doi-asserted-by":"crossref","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Frontiers in immunology"},{"key":"10.1016\/j.intimp.2022.108821_b0035","first-page":"137320","article-title":"Changes of immunological profiles in patients with chronic myeloid leukemia in the course of treatment","author":"Humlova","year":"2010","journal-title":"Clin. developmental immunol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108821_b0040","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1600-0609.2010.01501.x","article-title":"Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy","volume":"85","author":"Rohon","year":"2010","journal-title":"Eur. J.haematol."},{"key":"10.1016\/j.intimp.2022.108821_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.106273","article-title":"Role of cancer immunology in chronic myelogenous leukemia","volume":"88","author":"Ureshino","year":"2020","journal-title":"Leuk. Res."},{"key":"10.1016\/j.intimp.2022.108821_b0050","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fonc.2020.00109","article-title":"The Generation and Identity of Human Myeloid-Derived Suppressor Cells","volume":"10","author":"Bergenfelz","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.intimp.2022.108821_b0055","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. commun."},{"key":"10.1016\/j.intimp.2022.108821_b0060","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3389\/fimmu.2020.00938","article-title":"Myeloid Cell-Derived Arginase in Cancer Immune Response","volume":"11","author":"Grzywa","year":"2020","journal-title":"Frontiers in immunol."},{"issue":"10","key":"10.1016\/j.intimp.2022.108821_b0065","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.3390\/cells10102655","article-title":"Regulation of T Cells in Cancer by Nitric Oxide","volume":"10","author":"Navasardyan","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.intimp.2022.108821_b0070","first-page":"310","article-title":"Deep molecular response in chronic myeloid leukemia: the new goal of therapy?, Clinical cancer research : an official journal of the American Association for","volume":"20","author":"Mahon","year":"2014","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.intimp.2022.108821_b0075","doi-asserted-by":"crossref","first-page":"e101848","DOI":"10.1371\/journal.pone.0101848","article-title":"Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients","volume":"9","author":"Giallongo","year":"2014","journal-title":"PloS one"},{"issue":"7","key":"10.1016\/j.intimp.2022.108821_b0080","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41375-018-0175-0","article-title":"Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML","volume":"32","author":"Br\u00fcck","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2022.108821_b0085","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3389\/fonc.2015.00107","article-title":"Myeloid derived suppressor cells in chronic myeloid leukemia","volume":"5","author":"Giallongo","year":"2015","journal-title":"Frontiers in oncol."},{"issue":"5","key":"10.1016\/j.intimp.2022.108821_b0090","first-page":"2625","article-title":"Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review)","volume":"41","author":"Lee","year":"2019","journal-title":"Oncol. Rep."},{"issue":"2","key":"10.1016\/j.intimp.2022.108821_b0095","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41590-017-0022-x","article-title":"Myeloid-derived suppressor cells coming of age","volume":"19","author":"Veglia","year":"2018","journal-title":"Nat. Immunol."},{"issue":"16","key":"10.1016\/j.intimp.2022.108821_b0100","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.2174\/1568026617666161122121412","article-title":"Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy","volume":"17","author":"Wilkerson","year":"2017","journal-title":"Curr. Top Med. Chem."},{"key":"10.1016\/j.intimp.2022.108821_b0105","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3389\/fimmu.2020.01680","article-title":"The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion","volume":"11","author":"De Cicco","year":"2020","journal-title":"Frontiers in immunol."},{"key":"10.1016\/j.intimp.2022.108821_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104317","article-title":"Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis","volume":"363","author":"Cole","year":"2021","journal-title":"Cell Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2022.108821_b0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s13277-011-0254-6","article-title":"CD15+\/CD16low human granulocytes from terminal cancer patients: granulocytic myeloid-derived suppressor cells that have suppressive function","volume":"33","author":"Choi","year":"2012","journal-title":"Tumour Biol."},{"issue":"2","key":"10.1016\/j.intimp.2022.108821_b0120","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/jcmm.13326","article-title":"Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib","volume":"22","author":"Giallongo","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"6","key":"10.1016\/j.intimp.2022.108821_b0125","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1182\/blood-2004-07-2521","article-title":"Arginase I is constitutively expressed in human granulocytes and participates in fungicidal activity","volume":"105","author":"Munder","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2022.108821_b0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","article-title":"Myeloid-Derived Suppressor Cells","volume":"5","author":"Gabrilovich","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.intimp.2022.108821_b0135","doi-asserted-by":"crossref","first-page":"e954829","DOI":"10.4161\/21624011.2014.954829","article-title":"Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy","volume":"4","author":"Draghiciu","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.intimp.2022.108821_b0140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/nrc.2015.5","article-title":"NK cells and cancer: you can teach innate cells new tricks","volume":"16","author":"Morvan","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"6\u20137","key":"10.1016\/j.intimp.2022.108821_b0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1051\/medsci\/20183406013","article-title":"NK cells: a major role in the antitumoral immunomodulation in CML","volume":"34","author":"Toubert","year":"2018","journal-title":"Med. Sci. (Paris)"},{"issue":"9","key":"10.1016\/j.intimp.2022.108821_b0150","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1182\/blood-2016-10-745992","article-title":"CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors","volume":"129","author":"Hughes","year":"2017","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2022.108821_b0155","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/leu.2016.360","article-title":"Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia","volume":"31","author":"Ilander","year":"2017","journal-title":"Leukemia"},{"issue":"1\u20133","key":"10.1016\/j.intimp.2022.108821_b0160","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12026-013-8455-2","article-title":"Myeloid derived suppressor cells in physiological and pathological conditions: the good, the bad, and the ugly","volume":"57","author":"Serafini","year":"2013","journal-title":"Immunol. res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922003058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922003058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:39:58Z","timestamp":1761586798000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922003058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":32,"alternative-id":["S1567576922003058"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108821","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Abnormal immune function of MDSC and NK cells from chronic phase CML patients restores with tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.108821","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"108821"}}